The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose escalation and expansion safety study of BLZ-100 in subjects with skin cancer.
 
Dennis Michael Miller
Employment - Blaze Bioscience
Leadership - Blaze Bioscience
Stock and Other Ownership Interests - Blaze Bioscience
Consulting or Advisory Role - Columbia Northwest Pharmaceuticals; Durable Therapeutics; Global Blood Therapeutics; Resolve Therapeutics; Theraclone Sciences
Patents, Royalties, Other Intellectual Property - Blaze Bioscience
 
Miko Yamada
Research Funding - Blaze Bioscience (Inst)
 
Melinda Lowe
No Relationships to Disclose
 
Casey Rowe
Employment - Q-Pharm Pty Ltd
Travel, Accommodations, Expenses - Janssen
 
Dominic Wood
Employment - Primary Health
 
Kelly Byrnes-Blake
Consulting or Advisory Role - Blaze Bioscience
Patents, Royalties, Other Intellectual Property - Blaze Bioscience
 
Tarl Prow
Research Funding - Blaze Bioscience (Inst); LEO Pharma (Inst)
Patents, Royalties, Other Intellectual Property - University of Queensland
 
Lynda Spelman
Employment - Queensland Skin Cancer Foundation
Stock and Other Ownership Interests - Specialist Connect
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Blaze Bioscience (Inst); Celgene (Inst); Janssen (Inst); LEO Pharma (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Otsuka (Inst)